top of page

U.S. FDA Finds Manufacturing Lapses At Eli Lilly Plant

  • Writer: By The Financial District
    By The Financial District
  • Jan 21, 2024
  • 1 min read

US inspectors recently uncovered new manufacturing problems at an Eli Lilly plant that has been under scrutiny by federal investigators, according to government records obtained by Reuters, Marisa Taylor and Maggie Fick reported for Reuters.


The deficiencies detected included problems in tracking the manufacturing process and quality controls, as well as lapses in its calibration of equipment and failure to properly maintain facilities and equipment, the inspection report shows. I Photo: Momoneymoproblemz Wikimedia Commons



The US Food and Drug Administration (FDA) inspection in July at Lilly's Branchburg, New Jersey, plant detected eight separate deficiencies.


They included problems in tracking the manufacturing process and quality controls, as well as lapses in its calibration of equipment and failure to properly maintain facilities and equipment, the inspection report shows.


All the news: Business man in suit and tie smiling and reading a newspaper near the financial district.

The inspection report, obtained through a Freedom of Information Act (FOIA) request by Reuters, was partially redacted to remove the names of any products affected.


Lilly said in a statement to Reuters that the company had asked the FDA to allow for "additional flexibility" to manufacture migraine treatment Emgality on a different production line if needed in the future.




Optimize asset flow management and real-time inventory visibility with RFID tracking devices and custom cloud solutions.
Sweetmat disinfection mat

Comments


Register for News Alerts

  • LinkedIn
  • Instagram
  • X
  • YouTube

Thank you for Subscribing

TFD [LOGO] (10).png

WHERE BUSINESS CLICKS

TFD [LOGO].png

The Financial District®  2023

bottom of page